Literature DB >> 33407608

Anti-migraine agents from an immunological point of view.

Bakri M Assas1.   

Abstract

The new wave of anti-migraine agents is nothing less than a milestone in our battle to manage this devastating disease. However, concerns have recently increased regarding the safety of these drugs. CGRP, while known as a potent vasodilator, is also a key neural and immune modulator. The roles of CGRP in immune determination, have been studied in depth, with particular focus on its functional significance with respect to common immune challenges i.e., bacterial, viral, fungal and parasitic infections. This review discusses many potential areas of concern in regard to blocking CGRP function and its potential influence on immune milieus during infection, and the risk of adverse effects. Finally, this review recommends specific measures to be taken into consideration when administering anti-CGRP/CGRPR agents.

Entities:  

Keywords:  Adverse drug reactions; Immunology; Infectious disease; Inflammation; Neuroscience; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2021        PMID: 33407608      PMCID: PMC7789413          DOI: 10.1186/s12967-020-02681-6

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  92 in total

1.  The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.

Authors:  D J Williamson; S L Shepheard; R G Hill; R J Hargreaves
Journal:  Eur J Pharmacol       Date:  1997-06-05       Impact factor: 4.432

2.  Herpes Viruses and Senile Dementia: First Population Evidence for a Causal Link.

Authors:  Ruth F Itzhaki; Richard Lathe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Authors:  Marcelo E Bigal; David W Dodick; Alan M Rapoport; Stephen D Silberstein; Yuju Ma; Ronghua Yang; Pippa S Loupe; Rami Burstein; Lawrence C Newman; Richard B Lipton
Journal:  Lancet Neurol       Date:  2015-09-30       Impact factor: 44.182

4.  Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.

Authors:  P J Goadsby; L Edvinsson; R Ekman
Journal:  Ann Neurol       Date:  1990-08       Impact factor: 10.422

5.  Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.

Authors:  Theodoros V Giannouchos; Dimos-Dimitrios Mitsikostas; Robert L Ohsfeldt; Athanassios Vozikis; Paraskevi Koufopoulou
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

6.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

7.  Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype.

Authors:  M Levite
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

8.  Recombinant mouse calcitonin gene-related peptide secreted by Lactococcus lactis inhibits lipopolysaccharide-induced inflammatory response in macrophages.

Authors:  Fu Namai; Yoshinari Yamamoto; Takashi Sato; Tasuku Ogita; Takeshi Shimosato
Journal:  Anim Sci J       Date:  2018-10-07       Impact factor: 1.749

9.  Skin-bacteria communication: Involvement of the neurohormone Calcitonin Gene Related Peptide (CGRP) in the regulation of Staphylococcus epidermidis virulence.

Authors:  Awa R N'Diaye; Camille Leclerc; Takfarinas Kentache; Julie Hardouin; Cecile Duclairoir Poc; Yoan Konto-Ghiorghi; Sylvie Chevalier; Olivier Lesouhaitier; Marc G J Feuilloley
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

Review 10.  Animal models of migraine and experimental techniques used to examine trigeminal sensory processing.

Authors:  Andrea M Harriott; Lauren C Strother; Marta Vila-Pueyo; Philip R Holland
Journal:  J Headache Pain       Date:  2019-08-29       Impact factor: 7.277

View more
  5 in total

1.  Correction to: Anti-migraine agents from an immunological point of view.

Authors:  Mushref Bakri Assas
Journal:  J Transl Med       Date:  2021-08-09       Impact factor: 5.531

Review 2.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

Review 3.  AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System.

Authors:  Marika Marino; Matthew G Holt
Journal:  Front Neurol       Date:  2022-04-12       Impact factor: 4.086

4.  Xiongshao Zhitong Recipe Attenuates Nitroglycerin-Induced Migraine-Like Behaviors via the Inhibition of Inflammation Mediated by Nitric Oxide Synthase.

Authors:  Song Yang; Cong Chen; Xiaoyao Liu; Qianjun Kang; Quantao Ma; Pin Li; Yujie Hu; Jialin Li; Jian Gao; Ting Wang; Weiling Wang
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

Review 5.  Nutrients to Improve Mitochondrial Function to Reduce Brain Energy Deficit and Oxidative Stress in Migraine.

Authors:  Michal Fila; Cezary Chojnacki; Jan Chojnacki; Janusz Blasiak
Journal:  Nutrients       Date:  2021-12-10       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.